Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|June 3, 2011
New: Shimadzu News Pharma Special
Shimadzu has launched a Special Edition of the Shimadzu-News specifically for the needs of the pharmaceutical industry.
Advertisement
Shimadzu has launched a Special Edition of the Shimadzu-News specifically for the needs of the pharmaceutical industry. 40 pages introduce solutions and applications for a multitude of topics such as drug research, development and testing as well as method development, manufacturing and quality control.
The applications cover many disciplines of analytical instrumentation, e.g. chromatography, TOC and spectroscopy. In-detail, in-depth articles describe new as well as established methods. In a highly regulated environment, the pharmaceutical industry depends on increasingly sensitive measurements, and the same time efficiency, cost-effectiveness and ecology.
Some selected highlights: TOC analysis of ultra pure water, detection of heavy metals by EDX, impurity analysis by two dimensional LC and LCMS-IT-TOF, and extrusion testing of blister packaging. The new Crude2Pure system, jointly developed by Shimadzu Corporation and GlaxoSmithKline UK, demonstrates Shimadzu’s innovation and ability to provide tailor-made technologies.
Shimadzu Pharma News is available for download at
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement